This report was first published by Endpoints News. To see the original version, click here
There are countless diseases lacking a single good treatment, but drugmakers are still herding into the same targets, particularly in chasing after megablockbusters.
George Yancopoulos, the outspoken co-founder and chief scientific officer of Regeneron, is one of the loudest critics of this trend. “Even if they make something you take twice as less frequently, is that what they should be doing?” he said in an interview. “Give me a new drug that treats a new disease.”
您已阅读10%（560字），剩余90%（4779字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。